An epidemiOlogy Study to deteRmine the Prevalence of EGFR (Epidermal Growth Factor Receptor) muTations in RUSsian Patients With Advanced NSCLC (Non-Small Cell Lung Cancer).

Patient characteristics: Gender. Age. Race, ethnicity. Smoking habits. Family history of NSCLC.

Time frame: up to 18 months

Disease information/diagnostic procedures

Date of the cytological verification of the NSCLC diagnosis. Disease stage and TNM classification. Morphological classification. Extent of the disease. Performance Status ECOG, including at diagnosis

Time frame: up to 18 months

EGFR mutations profile in cytology and/or histology (depending on the availablility of samples) and plasma samples at the time of every progression or in 1.5 year follow up in case of no progression

Time frame: up to 18 months

Characteristics of the 1st line and subsequent lines of antitumor therapy

1st line and subsequent lines of therapy treatment, therapy regimen, medicines used for therapy (drugs by INN), for EGFRm+ patients - number of cycles of antitumor therapy, onset date, end date of each line

Time frame: up to 18 months

Clinical outcome/Patient response (for EGFRm+ patients who entered observation phase)

Treatment response/ progression of disease on every line of antitumor therapy: progressive disease, partial response, stable disease and complete response according to RECIST 1.1 evaluation and/or any other clinical assessment. Death: Disease-related or for other reasons

Time frame: up to 18 months